Genital Diseases, Female  >>  epacadostat (INCB024360)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epacadostat (INCB024360) / Incyte
NCT01685255 / 2012-001472-10: A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Terminated
2
83
Canada, US, Europe, RoW
Epacadostat, INCB024360, tamoxifen
Incyte Corporation
Ovarian Cancer, Genitourinary (GU) Tumors
10/14
10/14
NCT01982487: Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Withdrawn
1/2
0
US
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, vCP2292, IDO1 inhibitor INCB024360, INCB024360, indoleamine-2,3-dioxygenase inhibitor INCB024360, laboratory biomarker analysis, pharmacological study, pharmacological studies
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Epithelial Cancer, Stage IA Primary Peritoneal Cavity Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Epithelial Cancer, Stage IB Primary Peritoneal Cavity Cancer, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Epithelial Cancer, Stage IC Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
09/17
 
SEASCAPE, NCT02575807: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Terminated
1/2
35
Canada, US
CRS-207, Live, attenuated double-deleted Listeria monocytogenes (LADD), Epacadostat, INCB024360, IDO, Pembrolizumab, Keytruda®, Pembro
Aduro Biotech, Inc., Incyte Corporation
Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer
04/18
05/18

Download Options